Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include ANAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

NDAQ:AVXL - Post by User

Anavex Life Sciences Corp

Bullboard Posts

Post by kingposton Aug 17, 2015 3:08pm

121 Views

Post# 24025272

The secret key to most major deceases -- protein mis-folding

The leader targeting mis-folding proteins just happens to be Anavex AND there drugs 273 and the next up 371 both look effective and safe...
Misfolding protein deseases (massive list and counting):

-Alzheimers
-Epilepsy
-Parkinson
-Huntington
-Lou Garicks
-Diabetes type II
-Cancer
-Sickle Cell
-various blood deseases

Also could treat:
-depression
-concussion
-be used as a "smart pill" to improve everyones cognition

Bullboard Posts

@ the Bell: TSX advances to start off Christmas trading week